News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Allos Therapeutics (ALTH) stock leapt 37 percent in afternoon action.


Posted on: 12/09/2004

Allos Therapeutics (ALTH) stock leapt 37 percent in afternoon action.

The move comes after the Westminster, Colo.-based company said it plans to release updated survival results Friday for a Phase III trial of its Efaproxyn drug, as an adjunct to whole-brain radiation therapy for the treatment of brain tumors originating from breast cancer.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740